A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus

NCT00630825 · Completed

Last updated 2026-05-28

This clinical trial tests different doses of the medication LY2189265 in overweight adults with type 2 diabetes to see how it affects their blood sugar levels over time.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 262 people

Who can join Ages 18+ · all sexes

Timeline Started 2008-04 · est. completion 2009-01

Where 34 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT00630825 ↗

Description as written by the study sponsor.

To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus participants.

Treatments tested

LY2189265 also known as Dulaglutide Drug
Placebo Drug

Main thing measured	Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00630825 ↗